Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

TNF inhibitors confer benefits for hand osteoarthritis progression

17 Mar 2018

Treatment with tumour necrosis factor inhibitors (TNFi) appears to reduce the risk of radiographic hand osteoarthritis (OA) progression in distal interphalangeal (DIP) joints but not in proximal interphalangeal (PIP) joints for up to 10 years, according to a study.

Researchers examined the radiographs of 262 rheumatoid arthritis (RA) patients (mean age 52 years; 66 percent female) participating in the BeSt study. Radiographs were scored for osteophytes in DIP/PIP joints according to the Osteoarthritis Research Society International atlas (0–3; summed score 0–54) and according to the Kellgren–Lawrence (KL) score (0–4; summed score 0–72) at baseline and at 10-year follow-up.

TNFi treatment was assessed on visits every 3 months and evaluated in relation to hand OA using generalized linear models and generalized estimating equations.

Of the patients, 58 percent received treatment with TNFi, with a median duration of 42 months. At baseline, there were 143 (55 percent) who had hand OA in any IP joint based on the Osteoarthritis Research Society International osteophyte score.

TNFi treatment duration did not influence incidental hand OA on the patient level. However, every month of TNFi treatment reduced the risk (RR) of hand OA progression in DIP joints (relative risk [RR], 0.987; 95 percent CI, 0.978–0.996) but not in PIP joints.

On the joint level, the effect of TNFi treatment on hand OA progression was likewise evident in DIP joints (RR, 0.996; 0.991–1.000) but not in PIP joints. Results for the KL score did not differ with those for osteophyte score.

Although the effect sizes are small, the findings of the present study provide evidence for the influence of tumour necrosis factor-alpha in hand OA pathogenesis, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.